United Therapeutics (UTHR)

• Market cap: $16.1B
• 1 day: -1.70%
• 5 days: -2.65%
• 1 month: -1.87%
• 3 months: -1.70%
• 6 months: 2.70%
• Year to date: 0.24%
• 1 year: 64.75%
• 5 years: 237.60%
• 10 years: 133.95%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Employees: 1,168

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

113% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 45

41.39% more ownership

Funds ownership: 97.55% [Q3] → 138.94% (+41.39%) [Q4]

29% more repeat investments, than reductions

Existing positions increased: 259 | Existing positions reduced: 201

21% more call options, than puts

Call options by funds: $46M | Put options by funds: $37.9M

4% more funds holding

Funds holding: 616 [Q3] → 643 (+27) [Q4]

1% less capital invested

Capital invested by funds: $15.5B [Q3] → $15.4B (-$78.8M) [Q4]

35% less funds holding in top 10

Funds holding in top 10: 17 [Q3] → 11 (-6) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $475 32% upside
• Avg. target: $475 32% upside
• High target: $475 32% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

UBS Ashwani Verma 44% 1-year accuracy 8 / 18 met price target

32% upside $475

Buy Maintained

8 Jan 2025